Benralizumab 30 mg/ml

BIOLOGICAL2 trials

Sponsors

Aristotle University Of Thessaloniki, European EGPA Study Group

Conditions

Airway RemodelingAsthma; EosinophilicEosinophilic Granulomatosis With Polyangiitis (EGPA)

Phase 4

BenRalizumab Effect on Airway Remodeling in Severe asTHma

RecruitingNCT06288516

Aristotle University Of ThessalonikiAirway Remodeling, Asthma; Eosinophilic

Start: 2024-03-01End: 2026-06-01Target: 45Updated: 2024-03-04

Unknown Phase

Benralizumab Effectiveness in EGPA

RecruitingNCT07815886

European EGPA Study GroupEosinophilic Granulomatosis With Polyangiitis (EGPA)

Start: 2026-02-11End: 2028-02-11Target: 100Updated: 2026-09-11